BD specialist Ton Berkien appointed Chair at femtech start-up Gedea Biotech
Lund December 1, 2021. Femtech start-up Biotech today announces that Ton Berkien has been elected Chairman of the Board of Directors of Gedea Biotech. He replaces Olov Sterner, one of the founders of Gedea who continues as a board member.
The appointment further strengthens the Board of Directors business development expertise, with Berkien bringing 20 years of experience in business development, and M&A.
Ton Berkien holds a bachelor's degree in economics from Saxion University in the Netherlands and life science industry Diploma from PwC/Harvard Business School/IMD. Since starting as head of competitive intelligence at Ferring Pharmaceuticals in 2003, he has held a number of senior positions in leading life science companies including Nycomed/Takeda, Neuvolution and Amgen, primarily in business development. Currently he serves as Chief Business Offices for Norwegian biotech Ultimovacs. Ton has both Swedish and Dutch citizenship and lives in Sweden together with his family.
“Ton Berkien has extensive experience and expertise in business development. The recruitment of Ton will further strengthen the board and the company as we prepare for our planned upcoming partnering work with pHyph," says Annette Säfholm, CEO of Gedea.
“I am pleased that the owners have placed their confidence in me as chairman of Gedea and I am excited about the task," says Ton Berkien. “Gedea is a company with great potential and I look forward to working actively with the partnering process.”
For further information, please contact:
Ton Berkien, Chairman
Phone: 070-791 49 54
Email: info@gedeabiotech.com
About Gedea Biotech
Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, an antibiotic-free and effective treatment for bacterial vaginosis. The company has generated promising results for the treatment of vaginal fungal infection and further studies are planned. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion. Gedea Biotech was founded in 2015 in Lund, Sweden. https://gedeabiotech.com/.